Nivolumab plus ipilimumab in non-small-cell lung cancer

Juwon Kim; Sang W. Shin

doi:10.1056/NEJMc1916859

Nivolumab plus ipilimumab in non-small-cell lung cancer

Juwon Kim, Sang W. Shin

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	874
Number of pages	1
Journal	New England Journal of Medicine
Volume	382
Issue number	9
DOIs	https://doi.org/10.1056/NEJMc1916859
Publication status	Published - 2020 Feb 27

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMc1916859

Cite this

@article{04dc4a9383a9438abf9b31f97177f91b,

title = "Nivolumab plus ipilimumab in non-small-cell lung cancer",

author = "Juwon Kim and Shin, {Sang W.}",

note = "Funding Information: Dr. Bersanelli reports receiving research funds from Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis, and Sanofi and consulting and speaking fees from Bristol-Myers Squibb, Novartis, and Pfizer; Dr. Tiseo, receiving consulting and speaking fees from AstraZeneca, Pfizer, Eli Lilly, Bristol-Myers Squibb, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre and research grants from AstraZeneca and Boehringer Ingelheim; and Dr. Banna, receiving consulting and speaking fees from Janssen-Cilag, Boehringer Ingelheim, Roche, MSD, and AstraZeneca. No other potential conflict of interest relevant to this letter was reported.",

year = "2020",

month = feb,

day = "27",

doi = "10.1056/NEJMc1916859",

language = "English",

volume = "382",

pages = "874",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "9",

}

TY - JOUR

T1 - Nivolumab plus ipilimumab in non-small-cell lung cancer

AU - Kim, Juwon

AU - Shin, Sang W.

N1 - Funding Information: Dr. Bersanelli reports receiving research funds from Roche, Pfizer, Seqirus, AstraZeneca, Bristol-Myers Squibb, Novartis, and Sanofi and consulting and speaking fees from Bristol-Myers Squibb, Novartis, and Pfizer; Dr. Tiseo, receiving consulting and speaking fees from AstraZeneca, Pfizer, Eli Lilly, Bristol-Myers Squibb, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre and research grants from AstraZeneca and Boehringer Ingelheim; and Dr. Banna, receiving consulting and speaking fees from Janssen-Cilag, Boehringer Ingelheim, Roche, MSD, and AstraZeneca. No other potential conflict of interest relevant to this letter was reported.

PY - 2020/2/27

Y1 - 2020/2/27

UR - http://www.scopus.com/inward/record.url?scp=85080050446&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1916859

DO - 10.1056/NEJMc1916859

M3 - Article

C2 - 32101672

AN - SCOPUS:85080050446

VL - 382

SP - 874

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -

Nivolumab plus ipilimumab in non-small-cell lung cancer

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this